Diagnosis and treatment of polycythemia vera and possible future study designs of the PVSG

J. J. Michiels, T. Barbui, G. Finazzi, S. M. Fuchtman, J. Kutti, J. D. Rain, R. T. Silver, Ayalew Tefferi, J. Thiele

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

The present study describes clinicopathological criteria to distinguish the 5 sequential stages proposed by Wasserman et al in the natural history of newly diagnosed PV patients. The European Working Group on MPD (EWG.MPD) extended and modified the PVSG diagnostic criteria of PV by including bone marrow histopathology. From the results of prospective randomized studies in PV it became evident that new clinical trials in previously untreated PV patients should focus on comparing interferon-alpha, a non-leukemogenic approach, versus a potential leukemogenic myelosuppressive treatment modality, Hydroxyurea appears to he the least leukemogenic myelosuppressive agent in long-term prospective clinical PV-studies extending observation periods of more than 10 years. The rational for using IFN-alpha as a first-line treatment option in newly diagnosed PV-patient include its effectiveness to abate constitutional symptoms and to induce a complete remission thereby avoiding phlebotomy, iron deficiency, and macrocytosis associated with hydroxyurea. Moreover IFN-alpha may prevent or delay the development of postpolycythemic myelofibrosis if used early in the course of the disease. Clinicians will be reluctant to postpone the use of hydroxyurea in early stage PV as long as a conservative approach using phlebotomy aiming at a hematocrit below 0.45, plus low-dose aspirin for the control platelet function or anagrelide for the control platelet number is used to keep the patient healthy. Low-dose aspirin will prevent the microvascular thrombotic complications of thrombocythemia associated with PV in remission after phlebotomy, but lacks myelosuppressive activity. Control of megakaryocyte maturation and reduction of platelet production to normal (< 400 x 109/l) by relatively low, doses of anagrelide will predict a significant reduction of vascular complications in the early stages of PV, may prevent progression to myelofibrosis during follow-up of PV and very probable will postpone the use of hydroxyurea treatment for controlling the platelet count in PV. Large scale randomized clinical trials in PV are proposed, which should aim not only for clinical and hematological response, safety, efficacy, but should also assess toxicity, the need for phlebotomy and whether the development of progressive disease such as splenomegaly, pluritis, myelofibrotic myeloid metaplasia, spent phase, myelodysplasia and acute leukemia can be delayed or prevented by IFN-alpha as compared to a conservative approach of phlebotomy plus low-dose aspirin or anagrelide followed by hydroxyurea when signs of myeloproliferative activity became evident.

Original languageEnglish (US)
Pages (from-to)239-253
Number of pages15
JournalLeukemia and Lymphoma
Volume36
Issue number3-4
StatePublished - 2000

Fingerprint

Polycythemia Vera
Phlebotomy
Hydroxyurea
Primary Myelofibrosis
Aspirin
Platelet Count
Blood Platelets
Therapeutics
Thrombocytosis
Megakaryocytes
Splenomegaly
Natural History
Hematocrit
Interferon-alpha
Blood Vessels
Leukemia
Iron
Randomized Controlled Trials
Bone Marrow
Observation

Keywords

  • Clinical trials
  • Diagnosis
  • Polycythemia vera
  • Treatment

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Michiels, J. J., Barbui, T., Finazzi, G., Fuchtman, S. M., Kutti, J., Rain, J. D., ... Thiele, J. (2000). Diagnosis and treatment of polycythemia vera and possible future study designs of the PVSG. Leukemia and Lymphoma, 36(3-4), 239-253.

Diagnosis and treatment of polycythemia vera and possible future study designs of the PVSG. / Michiels, J. J.; Barbui, T.; Finazzi, G.; Fuchtman, S. M.; Kutti, J.; Rain, J. D.; Silver, R. T.; Tefferi, Ayalew; Thiele, J.

In: Leukemia and Lymphoma, Vol. 36, No. 3-4, 2000, p. 239-253.

Research output: Contribution to journalArticle

Michiels, JJ, Barbui, T, Finazzi, G, Fuchtman, SM, Kutti, J, Rain, JD, Silver, RT, Tefferi, A & Thiele, J 2000, 'Diagnosis and treatment of polycythemia vera and possible future study designs of the PVSG', Leukemia and Lymphoma, vol. 36, no. 3-4, pp. 239-253.
Michiels JJ, Barbui T, Finazzi G, Fuchtman SM, Kutti J, Rain JD et al. Diagnosis and treatment of polycythemia vera and possible future study designs of the PVSG. Leukemia and Lymphoma. 2000;36(3-4):239-253.
Michiels, J. J. ; Barbui, T. ; Finazzi, G. ; Fuchtman, S. M. ; Kutti, J. ; Rain, J. D. ; Silver, R. T. ; Tefferi, Ayalew ; Thiele, J. / Diagnosis and treatment of polycythemia vera and possible future study designs of the PVSG. In: Leukemia and Lymphoma. 2000 ; Vol. 36, No. 3-4. pp. 239-253.
@article{9b43a6ad3c604059af410e75473ff5ea,
title = "Diagnosis and treatment of polycythemia vera and possible future study designs of the PVSG",
abstract = "The present study describes clinicopathological criteria to distinguish the 5 sequential stages proposed by Wasserman et al in the natural history of newly diagnosed PV patients. The European Working Group on MPD (EWG.MPD) extended and modified the PVSG diagnostic criteria of PV by including bone marrow histopathology. From the results of prospective randomized studies in PV it became evident that new clinical trials in previously untreated PV patients should focus on comparing interferon-alpha, a non-leukemogenic approach, versus a potential leukemogenic myelosuppressive treatment modality, Hydroxyurea appears to he the least leukemogenic myelosuppressive agent in long-term prospective clinical PV-studies extending observation periods of more than 10 years. The rational for using IFN-alpha as a first-line treatment option in newly diagnosed PV-patient include its effectiveness to abate constitutional symptoms and to induce a complete remission thereby avoiding phlebotomy, iron deficiency, and macrocytosis associated with hydroxyurea. Moreover IFN-alpha may prevent or delay the development of postpolycythemic myelofibrosis if used early in the course of the disease. Clinicians will be reluctant to postpone the use of hydroxyurea in early stage PV as long as a conservative approach using phlebotomy aiming at a hematocrit below 0.45, plus low-dose aspirin for the control platelet function or anagrelide for the control platelet number is used to keep the patient healthy. Low-dose aspirin will prevent the microvascular thrombotic complications of thrombocythemia associated with PV in remission after phlebotomy, but lacks myelosuppressive activity. Control of megakaryocyte maturation and reduction of platelet production to normal (< 400 x 109/l) by relatively low, doses of anagrelide will predict a significant reduction of vascular complications in the early stages of PV, may prevent progression to myelofibrosis during follow-up of PV and very probable will postpone the use of hydroxyurea treatment for controlling the platelet count in PV. Large scale randomized clinical trials in PV are proposed, which should aim not only for clinical and hematological response, safety, efficacy, but should also assess toxicity, the need for phlebotomy and whether the development of progressive disease such as splenomegaly, pluritis, myelofibrotic myeloid metaplasia, spent phase, myelodysplasia and acute leukemia can be delayed or prevented by IFN-alpha as compared to a conservative approach of phlebotomy plus low-dose aspirin or anagrelide followed by hydroxyurea when signs of myeloproliferative activity became evident.",
keywords = "Clinical trials, Diagnosis, Polycythemia vera, Treatment",
author = "Michiels, {J. J.} and T. Barbui and G. Finazzi and Fuchtman, {S. M.} and J. Kutti and Rain, {J. D.} and Silver, {R. T.} and Ayalew Tefferi and J. Thiele",
year = "2000",
language = "English (US)",
volume = "36",
pages = "239--253",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "3-4",

}

TY - JOUR

T1 - Diagnosis and treatment of polycythemia vera and possible future study designs of the PVSG

AU - Michiels, J. J.

AU - Barbui, T.

AU - Finazzi, G.

AU - Fuchtman, S. M.

AU - Kutti, J.

AU - Rain, J. D.

AU - Silver, R. T.

AU - Tefferi, Ayalew

AU - Thiele, J.

PY - 2000

Y1 - 2000

N2 - The present study describes clinicopathological criteria to distinguish the 5 sequential stages proposed by Wasserman et al in the natural history of newly diagnosed PV patients. The European Working Group on MPD (EWG.MPD) extended and modified the PVSG diagnostic criteria of PV by including bone marrow histopathology. From the results of prospective randomized studies in PV it became evident that new clinical trials in previously untreated PV patients should focus on comparing interferon-alpha, a non-leukemogenic approach, versus a potential leukemogenic myelosuppressive treatment modality, Hydroxyurea appears to he the least leukemogenic myelosuppressive agent in long-term prospective clinical PV-studies extending observation periods of more than 10 years. The rational for using IFN-alpha as a first-line treatment option in newly diagnosed PV-patient include its effectiveness to abate constitutional symptoms and to induce a complete remission thereby avoiding phlebotomy, iron deficiency, and macrocytosis associated with hydroxyurea. Moreover IFN-alpha may prevent or delay the development of postpolycythemic myelofibrosis if used early in the course of the disease. Clinicians will be reluctant to postpone the use of hydroxyurea in early stage PV as long as a conservative approach using phlebotomy aiming at a hematocrit below 0.45, plus low-dose aspirin for the control platelet function or anagrelide for the control platelet number is used to keep the patient healthy. Low-dose aspirin will prevent the microvascular thrombotic complications of thrombocythemia associated with PV in remission after phlebotomy, but lacks myelosuppressive activity. Control of megakaryocyte maturation and reduction of platelet production to normal (< 400 x 109/l) by relatively low, doses of anagrelide will predict a significant reduction of vascular complications in the early stages of PV, may prevent progression to myelofibrosis during follow-up of PV and very probable will postpone the use of hydroxyurea treatment for controlling the platelet count in PV. Large scale randomized clinical trials in PV are proposed, which should aim not only for clinical and hematological response, safety, efficacy, but should also assess toxicity, the need for phlebotomy and whether the development of progressive disease such as splenomegaly, pluritis, myelofibrotic myeloid metaplasia, spent phase, myelodysplasia and acute leukemia can be delayed or prevented by IFN-alpha as compared to a conservative approach of phlebotomy plus low-dose aspirin or anagrelide followed by hydroxyurea when signs of myeloproliferative activity became evident.

AB - The present study describes clinicopathological criteria to distinguish the 5 sequential stages proposed by Wasserman et al in the natural history of newly diagnosed PV patients. The European Working Group on MPD (EWG.MPD) extended and modified the PVSG diagnostic criteria of PV by including bone marrow histopathology. From the results of prospective randomized studies in PV it became evident that new clinical trials in previously untreated PV patients should focus on comparing interferon-alpha, a non-leukemogenic approach, versus a potential leukemogenic myelosuppressive treatment modality, Hydroxyurea appears to he the least leukemogenic myelosuppressive agent in long-term prospective clinical PV-studies extending observation periods of more than 10 years. The rational for using IFN-alpha as a first-line treatment option in newly diagnosed PV-patient include its effectiveness to abate constitutional symptoms and to induce a complete remission thereby avoiding phlebotomy, iron deficiency, and macrocytosis associated with hydroxyurea. Moreover IFN-alpha may prevent or delay the development of postpolycythemic myelofibrosis if used early in the course of the disease. Clinicians will be reluctant to postpone the use of hydroxyurea in early stage PV as long as a conservative approach using phlebotomy aiming at a hematocrit below 0.45, plus low-dose aspirin for the control platelet function or anagrelide for the control platelet number is used to keep the patient healthy. Low-dose aspirin will prevent the microvascular thrombotic complications of thrombocythemia associated with PV in remission after phlebotomy, but lacks myelosuppressive activity. Control of megakaryocyte maturation and reduction of platelet production to normal (< 400 x 109/l) by relatively low, doses of anagrelide will predict a significant reduction of vascular complications in the early stages of PV, may prevent progression to myelofibrosis during follow-up of PV and very probable will postpone the use of hydroxyurea treatment for controlling the platelet count in PV. Large scale randomized clinical trials in PV are proposed, which should aim not only for clinical and hematological response, safety, efficacy, but should also assess toxicity, the need for phlebotomy and whether the development of progressive disease such as splenomegaly, pluritis, myelofibrotic myeloid metaplasia, spent phase, myelodysplasia and acute leukemia can be delayed or prevented by IFN-alpha as compared to a conservative approach of phlebotomy plus low-dose aspirin or anagrelide followed by hydroxyurea when signs of myeloproliferative activity became evident.

KW - Clinical trials

KW - Diagnosis

KW - Polycythemia vera

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=0033954268&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033954268&partnerID=8YFLogxK

M3 - Article

VL - 36

SP - 239

EP - 253

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 3-4

ER -